Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WV › Glen Dale › NPI 1144228305
Hospital

Reynolds Memorial Hospital, INC

Reynolds Memorial Hospital, INC was paid $14.90M by Medicaid between Jan 2018 and Dec 2024, across 242 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.

33Billing provider infoREYNOLDS MEMORIAL HOSPITAL, INC
GLEN DALE, WV 26038
33aNPI1144228305assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.90M
24GClaims431,331
24DCodes billed242
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in West Virginia

Rank by total paid#15 of 26
Median peer was paid$18.33M
This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201829,103$2.45M
201929,471$2.02M
202079,343$4.86M
202173,931$1.52M
202249,232$1.13M
202392,879$1.51M
2024incomplete77,372$1.42M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 11% 11,776 9,969 $1.63M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 8.8% 4,971 4,127 $1.32M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 8.6% 13,679 11,925 $1.27M
74177 Computed tomography, abdomen and pelvis; with contrast material 5.6% 2,327 1,957 $831K
80053 Comprehensive metabolic panel 3.7% 29,874 22,647 $552K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 3.4% 6,664 5,976 $508K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 3.2% 8,035 6,304 $473K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.3% 28,207 22,206 $337K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 2.2% 1,213 1,078 $324K
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.8% 3,987 3,509 $274K
74176 Computed tomography, abdomen and pelvis; without contrast material 1.8% 989 841 $263K
70450 Computed tomography, head or brain; without contrast material 1.7% 2,332 2,028 $259K
230 more codes
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 1.7% 3,560 $254K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 1.6% 8,054 $231K
96361 Intravenous infusion, hydration; each additional hour 1.5% 3,370 $227K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.4% 8,029 $202K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.3% 2,902 $195K
84443 Thyroid stimulating hormone (TSH) 1.3% 9,398 $193K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 1.3% 7,305 $187K
71046 Radiologic examination, chest; 2 views 1.2% 3,018 $180K
71045 Radiologic examination, chest; single view 1.2% 6,270 $179K
96375 Therapeutic injection; each additional sequential IV push 1.2% 6,712 $178K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.1% 1,206 $169K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 1.1% 4,062 $165K
81001 <1% 12,775 $136K
80061 Lipid panel <1% 6,613 $129K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 2,706 $127K
87081 <1% 10,250 $120K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 11,138 $116K
84484 <1% 5,495 $114K
J7120 Ringers lactate infusion, up to 1000 cc <1% 2,167 $114K
83690 <1% 5,058 $108K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 3,660 $104K
85027 <1% 9,010 $101K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 5,812 $99K
83735 <1% 6,912 $98K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 3,163 $92K
80048 Basic metabolic panel (calcium, ionized) <1% 5,974 $91K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,981 $85K
87086 Culture, bacterial; quantitative colony count, urine <1% 5,797 $82K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 3,955 $81K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,782 $79K
73630 <1% 1,209 $73K
71275 Computed tomographic angiography, chest, with contrast material <1% 400 $72K
83036 Hemoglobin; glycosylated (A1C) <1% 4,824 $71K
36415 Collection of venous blood by venipuncture <1% 18,353 $70K
82607 <1% 4,138 $68K
85610 <1% 3,978 $65K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,024 $63K
82550 <1% 2,738 $57K
87186 <1% 2,750 $55K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 2,094 $54K
81025 <1% 1,903 $54K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 524 $50K
77067 Screening mammography, bilateral, including computer-aided detection <1% 406 $50K
96376 <1% 1,597 $50K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 2,087 $49K
87040 <1% 1,400 $47K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 2,856 $44K
G0378 Hospital observation service, per hour <1% 1,083 $43K
85007 <1% 4,384 $41K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 619 $39K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,951 $38K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 811 $37K
97014 <1% 744 $36K
87077 <1% 2,159 $34K
85730 <1% 1,064 $33K
87070 <1% 1,247 $31K
73610 <1% 641 $31K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 967 $31K
76830 Ultrasound, transvaginal <1% 499 $31K
97161 <1% 684 $29K
83880 <1% 1,258 $28K
84439 <1% 1,827 $28K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 1,231 $28K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 293 $28K
72110 <1% 285 $27K
84466 <1% 2,097 $27K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 189 $27K
72125 Computed tomography, cervical spine; without contrast material <1% 482 $26K
83605 <1% 2,822 $26K
82728 <1% 1,974 $26K
86850 <1% 1,936 $26K
84703 <1% 1,439 $25K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 370 $25K
J7030 Infusion, normal saline solution , 1000 cc <1% 254 $25K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 287 $24K
83540 <1% 2,292 $24K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,591 $24K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,636 $22K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 1,244 $22K
82553 <1% 384 $22K
82746 <1% 1,684 $21K
74018 <1% 420 $20K
86900 <1% 1,929 $19K
99213 Doctor's office visit, returning patient (routine) <1% 589 $19K
73030 <1% 574 $18K
73562 <1% 452 $18K
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,863 $17K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 15 $17K
86803 <1% 1,242 $15K
86140 <1% 1,258 $14K
59025 Fetal non-stress test <1% 253 $14K
84702 <1% 531 $14K
36592 <1% 124 $14K
84550 <1% 850 $12K
87147 <1% 631 $12K
83615 <1% 1,357 $11K
87480 <1% 910 $11K
A9576 Injection, gadoteridol, (prohance multipack), per ml <1% 143 $11K
73130 <1% 215 $11K
82962 <1% 2,633 $10K
87660 <1% 908 $10K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 198 $10K
87510 <1% 908 $10K
73110 <1% 167 $10K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 1,234 $10K
85651 <1% 654 $10K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 458 $9K
J1170 Injection, hydromorphone, up to 4 mg <1% 655 $9K
76819 Fetal biophysical profile; without non-stress testing <1% 19 $9K
93041 <1% 141 $9K
96367 <1% 347 $8K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 187 $8K
82570 <1% 925 $8K
82803 <1% 597 $8K
81002 <1% 564 $8K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 599 $8K
87088 <1% 149 $8K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 942 $8K
87340 <1% 804 $7K
82248 <1% 1,988 $7K
76536 <1% 38 $7K
G0475 Hiv antigen/antibody, combination assay, screening <1% 689 $7K
85379 <1% 785 $7K
J0690 Injection, cefazolin sodium, 500 mg <1% 367 $6K
82565 <1% 227 $6K
86762 <1% 224 $6K
93971 <1% 52 $6K
72050 <1% 19 $6K
80050 General health panel <1% 156 $6K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 809 $6K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 435 $5K
94760 <1% 554 $5K
73564 <1% 170 $5K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 98 $5K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 87 $5K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 73 $5K
84153 <1% 213 $5K
82043 <1% 572 $5K
0064U <1% 87 $5K
86780 <1% 500 $4K
84156 <1% 210 $4K
90686 <1% 352 $4K
73590 <1% 32 $4K
20610 <1% 64 $4K
86618 <1% 273 $3K
87205 <1% 409 $3K
88142 <1% 153 $3K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 67 $3K
77063 Screening digital breast tomosynthesis, bilateral <1% 179 $3K
86901 <1% 1,415 $3K
84100 <1% 251 $3K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 144 $3K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 73 $2K
86787 <1% 193 $2K
90715 <1% 173 $2K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 68 $2K
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 94 $2K
51700 <1% 76 $2K
86038 <1% 103 $2K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 822 $2K
73502 <1% 112 $2K
J2060 Injection, lorazepam, 2 mg <1% 51 $2K
J2704 Injection, propofol, 10 mg <1% 1,503 $1K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 18 $1K
80179 <1% 158 $1K
85046 <1% 231 $1K
87430 <1% 206 $1K
20611 <1% 12 $1K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 46 $1K
86592 <1% 32 $1K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 12 $1K
90472 Immunization administration, each additional vaccine (list separately) <1% 85 $996.87
80143 <1% 140 $951.60
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 340 $851.03
99203 Doctor's office visit, new patient (routine) <1% 19 $816.97
86706 <1% 107 $789.44
84630 <1% 184 $779.24
83970 <1% 27 $770.31
85652 <1% 488 $769.74
90656 <1% 109 $754.43
84520 <1% 87 $754.40
93880 <1% 12 $735.23
82378 <1% 127 $717.64
86704 <1% 59 $632.69
80076 <1% 63 $613.11
J3475 Injection, magnesium sulfate, per 500 mg <1% 535 $593.96
J1650 Injection, enoxaparin sodium, 10 mg <1% 226 $530.00
84145 <1% 49 $525.81
71250 <1% 14 $494.18
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 300 $427.51
82947 <1% 127 $413.68
82950 <1% 73 $353.50
94727 <1% 26 $350.84
94060 <1% 27 $340.71
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 17 $340.04
93356 <1% 189 $262.89
88304 <1% 29 $257.48
88342 <1% 12 $243.72
94729 <1% 14 $222.31
G0008 Administration of influenza virus vaccine <1% 85 $212.07
87807 <1% 15 $187.14
82105 <1% 15 $180.37
93017 <1% 13 $175.48
0065U <1% 326 $146.65
J0780 Injection, prochlorperazine, up to 10 mg <1% 121 $140.96
Q3014 Telehealth originating site facility fee <1% 23 $131.87
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 145 $124.99
J1010 Injection, methylprednisolone acetate, 1 mg <1% 97 $95.35
84460 <1% 35 $90.74
84450 <1% 34 $85.87
J2550 Injection, promethazine hcl, up to 50 mg <1% 26 $80.46
86431 <1% 16 $78.44
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 314 $58.12
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 121 $53.98
J1040 Injection, methylprednisolone acetate, 80 mg <1% 17 $46.00
96127 <1% 13 $37.70
90694 <1% 54 $37.53
51798 <1% 19 $22.40
76376 <1% 264 $20.65
90653 <1% 19 $18.87
90460 Immunization administration through 18 years of age via any route, first or only component <1% 16 $10.62
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 49 $9.13
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 20 $8.49
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 14 $8.26
J0330 Injection, succinylcholine chloride, up to 20 mg <1% 14 $1.50
J3490 Unclassified drugs <1% 1,868 $1.35
J1171 Injection, hydromorphone, 0.1 mg 0% 17 $0.00
C9113 Injection, pantoprazole sodium, per vial 0% 25 $0.00
G1010 Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program 0% 19 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHESS, DAVD (CHIEF EXECUTIVE OFFICER)